Real-world treatment and outcomes of frontline chemotherapy in patients with metastatic pancreatic cancer.
← Data Quality Considerations for Determining the Impact of the COVID-19 Pandemic on Outpatient Visits and Procedures in the United StatesAmivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy →